anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method for saving and/or restoring settings of an instrument for processing a sample or reagent is disclosed. The instrument comprises a control unit and an operating system. A storage medium is provided to the instrument. The storage medium comprises a script. The script restores data for restoring settings of the instrument. The script is encrypted and/or digitally signed. The method verifies an identity and/or integrity of the script and executes the script upon starting the instrument by the operating system with the storage medium when the identity and/or integrity of the script correspond to an identity and/or integrity of the instrument. The control unit provides an input menu for allowing a user to input a saving and/or restoring command. The instrument saves settings on the storage medium and/or restores settings of the instrument from the storage medium by the restoring data corresponding to the saving and/or restoring command.
The SSB reduction intervention consists of 10-weeks of targeted, brief interactions with parents when they come to pick up their children for a center-based early childcare program. The sessions will be twice per week.
<P>PROBLEM TO BE SOLVED: To provide a ginkgo leaf extract which does not contain ginkgolic acid, contains conventional ginkgo leaf extract active ingredients, and exhibits a remarkable effect for activating brain cells.  <P>SOLUTION: This composition having a brain function-activating effect contains nano fine particle ginkgo leaf extract as an active ingredient. The ginkgo leaf extract not containing ginkgolic acid and produced by a breakdown method for crushing ginkgo leaf extract powder by a combination of a dry method with a wet method. The nano fine particles are ≤100 nm fine particles. The composition has a form selected from the group consisting of a seasoning, a food additive, a food raw material, a food, a drink, a health food, a health drink, a medicine/quasi drug, and a feed. The health food or drink is a food or drink which prevents or improves symptoms with a brain function-activating effect and is useful for patients having brain circulation metabolism disorders. The medicine/quasi drug is used for human or animals.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Participants with hypertension will submit blood and fecal samples for comparison to control participants with normal blood pressure. Control group will only donate fecal and blood samples and will not participate in the exercise intervention. Participants with hypertension will also perform 3 months of supervised aerobic exercise (5 days/week) and submit blood and fecal samples every 4 weeks until the completion of the study.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to a pharmaceutical composition containing c-kit-ligand and hemopoietic factor, method of enhancement of levels of stem cells in peripheral blood, antagonist of c-kit-ligand, antisense molecule of nucleic acid, method of enhancement of levels of stem cells in peripheral blood ex- vivo. Invention involves pharmaceutical composition based on c-kit-ligand that is a polypeptide encoded by nucleic acid SEQ ID NO:1 or natural hemopoietic variant of polypeptide and effective amount of hemopoietic factor, method of enhancement of levels of stem cells in peripheral blood using the indicated composition. Also, invention relates to antisense nucleic acids used as therapeutic agents and method of enhancement of levels of cells in peripheral blood ex-vivo including treatment of peripheral blood cells with indicated composition ex-vivo. EFFECT: development of novel hemopoietic agent. 14 cl, 35 dwg, 3 tbl, 3 ex
FIELD: cosmetology. SUBSTANCE: agent for skin care contains emulsifying wax, water, and it may additionally include biologically active substances in the form of vegetable extracts, propolis extract and/or extract of essential oils. Besides, agent may additionally contain oil fraction in the form of vegetable or animal fats, glycerine, common salt and/or sea salt, and also preservatives. Used water may contain silver ions. The agent retains moisture in skin thus normalizes water-salt metabolism. EFFECT: higher efficiency. 11 cl, 7 ex
INTRODUCTION: Changes to bone physiology play a central role in the development of osteoarthritis with the mechanosensing osteocyte releasing factors that drive disease progression. This study developed a humanised in vitro model to detect osteocyte responses to either interleukin-6, a driver of degeneration and bone remodelling in animal and human joint injury, or mechanical loading, to mimic osteoarthritis stimuli in joints.
METHODS: Human MSC cells (Y201) were differentiated in 3-dimensional type I collagen gels in osteogenic media and osteocyte phenotype assessed by RTqPCR and immunostaining. Gels were subjected to a single pathophysiological load or stimulated with interleukin-6 with unloaded or unstimulated cells as controls. RNA was extracted 1-hour post-load and assessed by RNAseq. Markers of pain, bone remodelling, and inflammation were quantified by RT-qPCR and ELISA.
RESULTS: Y201 cells embedded within 3D collagen gels assumed dendritic morphology and expressed mature osteocytes markers. Mechanical loading of the osteocyte model regulated 7564 genes (Padj p<0.05, 3026 down, 4538 up). 93% of the osteocyte transcriptome signature was expressed in the model with 38% of these genes mechanically regulated. Mechanically loaded osteocytes regulated 26% of gene ontology pathways linked to OA pain, 40% reflecting bone remodelling and 27% representing inflammation. Load regulated genes associated with osteopetrosis, osteoporosis and osteoarthritis. 42% of effector genes in a genome-wide association study meta-analysis were mechanically regulated by osteocytes with 10 genes representing potential druggable targets. Interleukin-6 stimulation of osteocytes at concentrations reported in human synovial fluids from patients with OA or following knee injury, regulated similar readouts to mechanical loading including markers of pain, bone remodelling, and inflammation.
DISCUSSION: We have developed a reproducible model of human osteocyte like cells that express >90% of the genes in the osteocyte transcriptome signature. Mechanical loading and inflammatory stimulation regulated genes and proteins implicated in osteoarthritis symptoms of pain as well as inflammation and degeneration underlying disease progression. Nearly half of the genes classified as 'effectors' in GWAS were mechanically regulated in this model. This model will be useful in identifying new mechanisms underlying bone and joint pathologies and testing drugs targeting those mechanisms.
All patients undergoing heart surgery using cardiopulmonary bypass who have a pre-operative Hb value greater than 90 g/L, no evidence of hypoxemia (SaO2 \> 90%) and no history of congenital methemoglobinemia. Exclusion criteria will include severe hypoxemia, acute or chronic renal failure requiring dialysis, emergency surgery or the lack of a PA catheter. Non invasive brain oximetry will be used to assess the brain oxygen tension during surgical procedure.
The intricate interplay of cancer stem cell plasticity, along with the bidirectional transformation between epithelial-mesenchymal states, introduces further intricacy to offer insights into newer therapeutic approaches. Differentiation therapy, while successful in targeting leukemic stem cells, has shown limited overall success, with only a few promising instances. Using colon carcinoma cell strains with sequential p53/p73 knockdowns, our study underscores the association between p53/p73 and the maintenance of cellular plasticity. Morphological alterations corresponding with cell surface marker expressions, transcriptome analysis and functional assays were performed to access stemness and EMT (Epithelial-Mesenchymal Transition) characteristics in the spectrum of cells exhibiting sequential p53 and p73 knockdowns. Notably, our investigation explores the effectiveness of esculetin in reversing the shift from an epithelial to a mesenchymal phenotype, characterized by stem cell-like traits. Esculetin significantly induces enterocyte differentiation and promotes epithelial cell polarity by altering Wnt axes in Cancer Stem Cell-like cells characterized by high mesenchymal features. These results align with our previous findings in leukemic blast cells, establishing esculetin as an effective differentiating agent in both Acute Myeloid Leukemia (AML) and solid tumor cells.
The aim of the study is to analyze ventricular-vascular properties with different ventricular-arterial coupling (VAC) ratio in the preeclamptic women. Seventy-seven pregnant women with preeclampsia and eighty-nine with normal pregnancy were performed echocardiography. VAC was defined as the ratio between aortic elastance (Ea) and left ventricular (LV) end-systolic elastance (Ees). Using the VAC value of 0.8 as the cut-off near uncoupling, the preeclampsia cases were divided into two subgroups: VAC ratio ≥ 0.8 and <0.8. Cardiac structure and function, VAC properties, as well as four components of the LV pressure-strain loop, including global myocardial work index (GWI), constructive work (GCW), wasted work (GWW), and work efficiency (GWE) were determined. The preeclampsia with VAC ≥ 0.8 had an enlarger indexed ventricular volume and a thicker relative ventricular wall than the VAC < 0.8. The Ees significantly increased in the subgroup with VAC < 0.8 and decreased in the VAC ≥ 0.8, while the Ea increased in both of them. The preeclampsia with VAC ≥ 0.8 showed an obvious augmentation in GWI, GCW and GWE, along with a similar GWW compared to those with VAC < 0.8. There were variable relationships between the LV pressure-strain components and VAC properties. Thus, the preeclampsia with VAC ≥ 0.8 undergoes a more adverse remodeling and a greater impact on cardiac contractility. The increased stiffness of the heart and arterial system, and increased resistance of peripheral vessels net lead to the deteriorative ventricular efficiency with elevated myocardial oxygen consumption during a preeclampsia pregnancy.
The method for preventing intraoperative and early postoperative intrapleural bleeding following surgery for the tuberculosis of lungs and pleura comprises the thorough hemostasis by electrocoagulation and the tamponage with the gauze swabs soaked in the hot isotonic solution. Furthermore, Aprotinine at a dose of 500,000 KIU is administered intravenously intraoperatively. Then the troubled areas of the lung and the thoracic wall are laid round with the gauze swabs soaked in Aprotinine solution. On the first day postoperatively, Aprotinine at a dose of 200,000 KIU every 6 hours is administered intravenously. On the second day, the dose of Aprotinine is 200,000 KIU thrice a day. On the third day – 200,000 KIU twice a day. In the case of the massive intraoperative diffuse hemorrhages, the freshly frozen plasma of the same group is transfused in a volume of 5-10 mL/kg for 30 minutes. In 8 hours postoperatively, the freshly frozen plasma of the same group is transfused in a volume of 5 mL/kg when the hemoglobin content in exudate exceeds half of the blood hemoglobin content. At the end of the surgery, sanitization fibrobronchoscopy is provided. The drainages are connected to aspiration immediately after bringing the ribs together. The lungs are gradually inflated.
BACKGROUND: Pulmonary fibrosis (PF) leads to excessive deposition of fibrous connective tissue in the lungs, increasing the risk of lung cancer due to the enhanced activity of fibroblasts (FBs). Fibroblast-mediated collagen fiber deposition creates a tumor-like microenvironment, laying the foundation for tumorigenesis. Clinically, numerous cases of lung cancer induced by pulmonary fibrosis have been observed. In recent years, the study of nucleotide point mutations, which provide more detailed insights than gene expression, has made significant advancements, offering new perspectives for clinical research.
METHODS: We initially employed Mendelian randomization to ascertain that the initial stage of lung cancer induced by PF belongs to small cell lung cancer (SCLC). Subsequently, pulmonary neuroendocrine cells (PNECs) were identified by using pseudo-time series analysis as cell clusters with carcinogenic potential. We categorized FBs into four groups according to their cellular metabolism, and then analyzed the cellular communication between FBs and PNECs, as well as changes in intracellular pathways of PNECs. Additionally, we examined the characteristic genome of FBs which is significantly associated with PF and investigated the impact of FBs on immune cells in the PF microenvironment. Finally, we explored strategies for preventing the progression from PF to lung cancer.
RESULTS: The genetic features of cells with carcinogenic potential in PF tissues were revealed, characterized by upregulation of Achaete-Scute Family BHLH Transcription Factor 1 (ASCL1), Homeobox B2 (HOXB2), Teashirt Zinc Finger Homeobox 2 (TSHZ2), Insulinoma-associated 1 (INSM1), and reduced activity of RE1 Silencing Transcription Factor (REST). FBs characterized by high glycolysis and low tricarboxylic acid (TCA) cycling played a key role in the progression of PF. The microenvironment of PF resembles the tumor microenvironment, providing a conducive immunosuppressive environment for the occurrence of cancer cells. In dendritic cells, rs9265808 is a susceptibility locus for progression from pulmonary fibrosis to lung cancer, mutations at this locus increase the expression of Complement Factor B (CFB), and excessive activation of the complement pathway is a crucial factor leading to lung cancer development in patients with pulmonary fibrosis. Ensuring adequate nutritional supply and physical function is one of the effective measures to prevent progression from pulmonary fibrosis to lung cancer.
CONCLUSION: CFB promotes lung cancer occurrence by inducing the accumulation and polarization of a large number of monocytes/macrophages in the lungs, driving disease progression by reducing the physical fitness of patients with pulmonary fibrosis.
Participants in Base Study P06029 received a single injection of 150 ug corifollitropin alfa on Stimulation Day 1 and daily injections of placebo-recFSH from Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.
Stabilized bacterial vaccines of low toxicity, good stability and high antigenicity are obtained by the treatment of aqueous suspensions of living or dead bacteria containing active bacterial antigens with a water-soluble chromium salt.  To destroy the autolytic enzyme without inactivating the antigen, the bacterial suspension is disinfected with, e.g. alcohol, 1 per cent formalin or 0.02 per cent aqueous merthiolate (sodium ethyl mercuri thiosalicylate) before, or simultaneously with the chrome treatment. The chrome treatment is in an acid medium preferably of pH 4 to 6. The pH is regulated by the addition of basic substances, e.g. sodium thiosulphate, sodium carbonate and sodium bicarbonate or by organic or inorganic acids, e.g. sulphuric or hydrochloric.  The toxicity of the product is decreased with increased concentration of chromium salt but the tendency for undesirable local effects at the site of injection is increased. The vaccines may be injected or taken orally. Specified chromium salts are chrome-alum, chromic nitrate, chromium sulphate, chromic chloride, chromous chloride, potassium chromate, potassium bichromate, sodium chromate and sodium bichromate. Examples describe the preparation of the following vaccines (a) Typhoid and Para Typhoid A and B bacillus (b) Depentery (Shig. dysenteriae and others) (c) Whooping Cough (Hemophilus pertussis) (d) Salmonella abortus equi (e) Vibrio cholerae.  Other specified bacteria are Pasturellua pestis, Bact. tularense, Mycobacterium tuberculosis and Brucella.
<P>PROBLEM TO BE SOLVED: To provide a method for searching a lymphocyte chemoattractant factor and a method for using the same.  <P>SOLUTION: The purified DNA encoding a LCF and the recombinant protein expressed from such DNA are disclosed. The LCF fragment or analog exhibits a LCF agonist or antagonist activity. The method for suppressing a LCF-CD4 interaction and the method for screening a candidate LCF agonist or antagonist are provided. The composition and a method useful for stimulating proliferation of CD4<SP>+</SP>T-cell in a mammal are also provided.  <P>COPYRIGHT: (C)2009,JPO&INPIT
PROBLEM TO BE SOLVED: To obtain a glycoprotein or a mixture thereof, having anticancer activities, activities for inhibiting and suppressing synthesis of DNA, and activities for inducing cancer cell apoptosis, and further having an asparagine-type sugar chain which has protease activities, and 34-83 kDa molecular weight, and further to provide a microorganism for producing the glycoprotein, a production method and use thereof. SOLUTION: This glycoprotein capable of being adsorbed on Con. A, and having an asparagine-type sugar chain and 34-83 kDa molecular weight, or a mixture thereof is obtained by culturing microorganisms capable of producing the glycoprotein capable of being adsorbed on the Con. A, and having the asparagine-type sugar chain and the 34-83 kDa molecular weight, and belonging to the genus Aspergillus, and gathering the glycoprotein capable of being adsorbed on the Con. A, and having the asparagine- type sugar chain and the 34-83 kDa molecular weight from the cultured material. The glycoprotein having an anticancer activities is useful for metastasis control of solid carcinoma, ascites-type cancer, polymorphic cell sarcoma and a cancer, and treatment of oral tumor.
Pyroptosis is a type of programmed cell death characterized by cell swelling and osmotic lysis, resulting in cytomembrane rupture and release of immunostimulatory components, which play a role in several pathological processes. Significant cellular responses to various stimuli involve the formation of inflammasomes, maturation of inflammatory caspases, and caspase-mediated cleavage of gasdermin. The function of pyroptosis in disease is complex but not a simple angelic or demonic role. While inflammatory diseases such as sepsis are associated with uncontrollable pyroptosis, the potent immune response induced by pyroptosis can be exploited as a therapeutic target for anti-tumor therapy. Thus, a comprehensive review of the role of pyroptosis in disease is crucial for further research and clinical translation from bench to bedside. In this review, we summarize the recent advancements in understanding the role of pyroptosis in disease, covering the related development history, molecular mechanisms including canonical, non-canonical, caspase 3/8, and granzyme-mediated pathways, and its regulatory function in health and multiple diseases. Moreover, this review also provides updates on promising therapeutic strategies by applying novel small molecule inhibitors and traditional medicines to regulate pyroptosis. The present dilemmas and future directions in the landscape of pyroptosis are also discussed from a clinical perspective, providing clues for scientists to develop novel drugs targeting pyroptosis.
ABSTRACT OF THE DISCLOSURE         Novel bisamidine compounds and processes for their preparation are provided herein.  The compounds have the structure   (Structure 3) in which Het is a 5- or 6-membered fully unsaturated heterocycle containing at least one nitrogen atom and optionally substituted by lower alkyl, tri-fluoromethyl, hydroxymethyl, halogen, hydroxy, lower alkoxy or amino; Z is sulphur; m is 1; n is 2; R is hydrogen or C1-4 lower alkyl; each of X1 and X2 is an imino group NY, where Y is hydrogen or cyano; and q is a number from 2 to 12.  Such compounds have useful histamine H antagonist activity.  For example, they inhibit histamine-stimulated secretion of gastric acid from the lumen-perfused stomachs of rats anaesthetized with urethane, at doses of from 0.5 to 256 micromoles per kilogram intravenous-ly.  They also inhibit the actions of histamine on the isolated guinea pig atrium and isolated rat uterus.  In addition, they inhibit the basal secretion of gastric acid and also that stimulated by pentagastrin or by food.
See illustrated Patient's Instructions for Use. 

The action of Xopenex (levalbuterol HCl) Inhalation Solution may last up to 8 hours. Xopenex Inhalation Solution should not be used more frequently than recommended. Do not increase the dose or frequency of dosing of Xopenex Inhalation Solution without consulting your physician. If you find that treatment with Xopenex Inhalation Solution becomes less effective for symptomatic relief, your symptoms become worse, and/or you need to use the product more frequently than usual, you should seek medical attention immediately. While you are taking Xopenex Inhalation Solution, other inhaled drugs and asthma medications should be taken only as directed by your physician. Common adverse effects include palpitations, chest pain, rapid heart rate, headache, dizziness, and tremor or nervousness. If you are pregnant or nursing, contact your physician about the use of Xopenex Inhalation Solution. 

Effective and safe use of Xopenex Inhalation Solution requires consideration of the following information in addition to that provided under Patient's Instructions for Use: 

Xopenex Inhalation Solution single-use low-density polyethylene (LDPE) vials should be protected from light and excessive heat. Store in the protective foil pouch between 20°C and 25°C (68°F and 77°F) [see USP Controlled Room Temperature]. Do not use after the expiration date stamped on the container. Unused vials should be stored in the protective foil pouch. Once the foil pouch is opened, the vials should be used within 2 weeks. Vials removed from the pouch, if not used immediately, should be protected from light and used within 1 week. Discard any vial if the solution is not colorless. 

The drug compatibility (physical and chemical), efficacy, and safety of Xopenex Inhalation Solution when mixed with other drugs in a nebulizer have not been established.
Exposure to ultraviolet B (UVB) radiation represents a significant environmental threat to human skin. This study investigates the protective mechanism of Artemisia Capillaris Thunb. (AC) extract against UVB-induced apoptosis and inflammation in HaCaT keratinocytes. AC extract demonstrated a significant protective effect, as evidenced by reduced early apoptosis, late apoptosis, and necrosis, as well as decreased apoptotic cell status upon UVB exposure. Additionally, AC extract effectively inhibited UVB-induced DNA damage, as indicated by diminished γ-H2AX foci formation. Restoration of mitochondrial damage and normalization of mitochondrial membrane potential, along with the reduction of intracellular and mitochondrial reactive oxygen species (ROS) levels, were observed with AC extract pre-treatment. The extract also exhibited anti-inflammatory properties, evidenced by the decreased release of IL-1α, IL-6, and PGE2 from keratinocytes. Additional research on the molecular mechanisms uncovered that the AC extract alters the cGAS/STING pathway, suppressing the mRNA (cGAS, STING, IRF3, IRF7 and TBK1) and protein levels (cGAS, STING, IRF3, IRF7 and NF-κB) linked to this particular pathway. The HPLC analysis identified chlorogenic acid and its derivatives as the major components in AC, constituting up to 16.44% of the total chlorogenic acid content. The cGAS/STING signaling pathway was found to be suppressed by chlorogenic acid and its derivatives, as indicated by molecular docking studies and RT-qPCR analysis. This suppression contributes to the protective effects against cell apoptosis and inflammation induced by UVB. To summarize, AC extract, which is abundant in chlorogenic acid and its derivatives, shows potential in protecting keratinocytes from damage caused by UVB by regulating the cGAS/STING signaling pathway.